{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:15:22Z","timestamp":1790950522831,"version":"4.1.0"},"reference-count":0,"publisher":"Australian Centre for Disease Control","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Commun Dis Intell (2018)"],"abstract":"<jats:p>Introduction: Tuberculin skin testing (TST) has been the accepted Australian standard for investigating contacts following exposure to infectious tuberculosis (TB). In recent years, the availability of the interferon-gamma release assays (IGRA) has introduced a potential alternative test but data on its use in this context are limited.Methods: A prospective longitudinal cohort study was conducted from 2008\u20132013 to review the use of IGRA and subsequent TB disease following testing in a state-wide contact tracing program. Additional information on the experience and acceptability of IGRA in this context was also obtained through program staff surveys following implementation.Results: IGRA testing was performed on 643 contacts, with a mean follow-up of 3.7 years. IGRA was primarily used to supplement TST, most commonly due to borderline TST reactivity in individuals who had bacille Calmette-Gu\u00e9rin vaccination. Where both TST and IGRA were performed, correlation of test results was poor (kappa=0.35). The negative predictive value for later development of active TB was 99.5%.Conclusions: Our experience suggests that IGRA are able to be incorporated safely and effectively as a supplement to TST-based contact tracing. Commun Dis Intell 2015;39(2):E191\u2013E196.<\/jats:p>","DOI":"10.33321\/cdi.2015.39.16","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T21:58:57Z","timestamp":1749592737000},"page":"191-196","source":"Crossref","is-referenced-by-count":4,"title":["Supplemental use of an interferon-gamma release assay in a state-wide tuberculosis contact tracing program in Victoria: a six-year review"],"prefix":"10.33321","volume":"39","author":[{"given":"Karen M","family":"Goebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee L","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18788","published-online":{"date-parts":[[2015,6,1]]},"container-title":["Communicable Diseases Intelligence"],"original-title":[],"link":[{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/download\/956\/2241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/download\/956\/2241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T21:59:09Z","timestamp":1749592749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/view\/956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.33321\/cdi.2015.39.16","relation":{},"ISSN":["2209-6051"],"issn-type":[{"value":"2209-6051","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}